Business Description
Johnson & Johnson
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
JNJ.USA0R34.UKJNJB34.BrazilJNJ.ArgentinaJNJ.CanadaJNJ.GermanyJNJ.MexicoJNJ.ChileJNJ.AustriaJNJ_KZ.KazakhstanJNJ.SwitzerlandJNJ.PeruJNJ.Ukraine IPO Date
2015-08-06Description
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.63 | |||||
| Equity-to-Asset | 0.39 | |||||
| Debt-to-Equity | 0.61 | |||||
| Debt-to-EBITDA | 1.89 | |||||
| Interest Coverage | 31.59 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.78 | |||||
| Beneish M-Score | -2.36 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 5.2 | |||||
| 3-Year EBITDA Growth Rate | 5.8 | |||||
| 3-Year EPS without NRI Growth Rate | 6.1 | |||||
| 3-Year FCF Growth Rate | -4.6 | |||||
| 3-Year Book Growth Rate | 9.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 2.76 | |||||
| Future 3-5Y Total Revenue Growth Rate | 0.81 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | -3.87 | |||||
| 12-1 Month Momentum % | -3.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.12 | |||||
| Quick Ratio | 0.88 | |||||
| Cash Ratio | 0.53 | |||||
| Days Inventory | 139.04 | |||||
| Days Sales Outstanding | 60.71 | |||||
| Days Payable | 117.9 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.91 | |||||
| Dividend Payout Ratio | 0.93 | |||||
| 3-Year Dividend Growth Rate | 5.9 | |||||
| Forward Dividend Yield % | 2.98 | |||||
| 5-Year Yield-on-Cost % | 3.89 | |||||
| 3-Year Average Share Buyback Ratio | 0.2 | |||||
| Shareholder Yield % | 0.98 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 67.09 | |||||
| Operating Margin % | 25.5 | |||||
| Net Margin % | 13.35 | |||||
| ROE % | 17.46 | |||||
| ROA % | 7.03 | |||||
| ROIC % | 14.82 | |||||
| ROC (Joel Greenblatt) % | 86.74 | |||||
| ROCE % | 12.62 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 32.19 | |||||
| Forward PE Ratio | 14.49 | |||||
| PE Ratio without NRI | 32.19 | |||||
| Shiller PE Ratio | 25.2 | |||||
| Price-to-Owner-Earnings | 29.92 | |||||
| PEG Ratio | 7.15 | |||||
| PS Ratio | 4.29 | |||||
| PB Ratio | 5.5 | |||||
| Price-to-Free-Cash-Flow | 28.88 | |||||
| Price-to-Operating-Cash-Flow | 22.02 | |||||
| EV-to-EBIT | 23.49 | |||||
| EV-to-Forward-EBIT | 13.69 | |||||
| EV-to-EBITDA | 16.4 | |||||
| EV-to-Forward-EBITDA | 12.03 | |||||
| EV-to-Revenue | 4.04 | |||||
| EV-to-Forward-Revenue | 4.47 | |||||
| EV-to-FCF | 27.5 | |||||
| Price-to-Projected-FCF | 1.76 | |||||
| Price-to-DCF (Earnings Based) | 2.8 | |||||
| Price-to-DCF (FCF Based) | 2.49 | |||||
| Price-to-Median-PS-Value | 0.93 | |||||
| Earnings Yield (Greenblatt) % | 4.26 | |||||
| Forward Rate of Return (Yacktman) % | 6.39 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Johnson & Johnson Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 97,773 | ||
| EPS (TTM) ($) | 4.94 | ||
| Beta | 0 | ||
| Volatility % | 7.82 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0.010486 | ||
| 20-Day SMA ($) | 159.57 | ||
| 12-1 Month Momentum % | -3.87 | ||
| 52-Week Range ($) | 159.57 - 166 | ||
| Shares Outstanding (Mil) | 2,408.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Johnson & Johnson Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Johnson & Johnson Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Johnson & Johnson Frequently Asked Questions
What is Johnson & Johnson(LIM:JNJ)'s stock price today?
The current price of LIM:JNJ is $159.57. The 52 week high of LIM:JNJ is $166.00 and 52 week low is $159.57.
When is next earnings date of Johnson & Johnson(LIM:JNJ)?
The next earnings date of Johnson & Johnson(LIM:JNJ) is 2023-10-17.
Does Johnson & Johnson(LIM:JNJ) pay dividends? If so, how much?
The Dividend Yield %  of Johnson & Johnson(LIM:JNJ) is 2.91% (As of Today), Highest Dividend Payout Ratio of Johnson & Johnson(LIM:JNJ) was 7.06. The lowest was 0.48. And the median was 0.58. The  Forward Dividend Yield % of Johnson & Johnson(LIM:JNJ) is 2.98%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers